Compare CFFN & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFFN | EVO |
|---|---|---|
| Founded | 1893 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2010 | N/A |
| Metric | CFFN | EVO |
|---|---|---|
| Price | $9.10 | $1.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $7.25 | $7.00 |
| AVG Volume (30 Days) | ★ 793.2K | 50.4K |
| Earning Date | 04-29-2026 | 04-08-2026 |
| Dividend Yield | ★ 4.51% | N/A |
| EPS Growth | ★ 79.31 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $16,300,000.00 | N/A |
| Revenue This Year | $20.16 | $1.37 |
| Revenue Next Year | $6.62 | $10.05 |
| P/E Ratio | $27.63 | ★ N/A |
| Revenue Growth | ★ 6.54 | N/A |
| 52 Week Low | $5.72 | $1.90 |
| 52 Week High | $9.10 | $4.27 |
| Indicator | CFFN | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 71.35 | 29.22 |
| Support Level | $7.49 | N/A |
| Resistance Level | N/A | $3.84 |
| Average True Range (ATR) | 0.23 | 0.05 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 79.41 | 24.32 |
Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.